2025
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review
Getz T, Bakirhan K, Seropian S, Shallis R. Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals Of Hematology 2025, 104: 3889-3892. PMID: 40576687, PMCID: PMC12334448, DOI: 10.1007/s00277-025-06388-w.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaT(8;21) acute myeloid leukemiaDeep remissionKIT mutationsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationCore binding factor acute myeloid leukemiaHematopoietic stem cell transplantationTreatment of acute myeloid leukemiaFavorable risk diseaseStem cell transplantationTyrosine kinase inhibitorsT(8;21)Based chemotherapyOverall survivalSystemic mastocytosisCell transplantationRisk diseaseTargeted therapyCase reportKinase inhibitorsClinical challengeT(8;21Clinical investigationAvapritinibTreat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh S, Nguyen J, Fudman D, Gerich M, Shah S, Hudesman D, McConnell R, Lukin D, Flynn A, Hwang C, Sprung B, Gaidos J, Mattar M, Rubin D, Hashash J, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy J, Ananthakrishnan A, Cross R, Gaytan J, Gurrola E, Patel S, Siegel C, Melmed G, Weaver S, Power S, Zou G, Jairath V, Hou J. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterology 2025, 12: e001615. PMID: 40164445, PMCID: PMC11962770, DOI: 10.1136/bmjgast-2024-001615.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAdvanced therapiesTreat-to-targetSymptomatic remissionBowel inflammationOpen-labelAsymptomatic patientsPatient-Centered Outcomes Research InstituteBowel diseaseControlled TrialsSafety of switchingClinical practiceActive bowel inflammationReduced bowel inflammationDeep remissionEndoscopic remissionTreatment failurePrimary endpointRandomised controlled trialsTargeted immunomodulationRemissionTherapyPatientsGood clinical practiceInformed consent
2023
A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults
Luskin M, Murakami M, Keating J, Winer E, Garcia J, Stahl M, Wadleigh M, Flamand Y, Neuberg D, Galinsky I, Leonard R, Hagopian E, Weizer C, McLanahan C, Stone R, Wang E, Stock W, DeAngelo D. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. Blood 2023, 142: 965. DOI: 10.1182/blood-2023-174246.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaDose-limiting toxicityMaximum tolerated doseStem cell transplantationPhase I studyCML-LBCDose escalationAllogeneic stem cell transplantationBCR-ABL1-positive acute lymphoblastic leukemiaCell line xenograft modelsPatient-derived xenograft modelsBlast phase CMLEscalating daily dosesPhase 2 doseLymphoid blast crisisBiomarkers of responseDurability of responseChronic myeloid leukemiaABL1 inhibitorsDose expansionEscalating dosesBlast crisisDeep remissionExpansion cohortTolerated dosePredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical records
2022
PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Inflammatory Bowel Diseases 2022, 28: s47-s48. DOI: 10.1093/ibd/izac015.073.Peer-Reviewed Original ResearchRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionHistological remissionClinical relapseUlcerative colitisDisease durationEndoscopic remissionCumulative riskMedian follow-up timeDuration of follow-upPredictive of clinical relapseMedian disease durationFollow-up timeRetrospective cohort studyPredictors of relapseMayo endoscopic scoreTufts Medical CenterPatient-reported outcomesMedian ageRelapse rateRelapse riskEndoscopic scoreElectronic medical records
2019
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia
Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. Blood Reviews 2019, 43: 100650. PMID: 31883804, DOI: 10.1016/j.blre.2019.100650.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid leukemiaHard clinical outcomesClinical trial evidenceMeasurable residual diseaseResidual leukemic cellsRisk of relapseApprovable endpointsMRD statusDeep remissionMorphologic remissionMRD assessmentOverall survivalMRD levelsClinical outcomesDisease relapseInitial treatmentResidual diseaseTrial evidenceClinical trialsTreatment decisionsSurrogate endpointsBone marrowPreemptive interventionLeukemic cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply